Ignite Creation Date:
2025-12-24 @ 12:22 PM
Ignite Modification Date:
2026-01-04 @ 4:55 AM
Study NCT ID:
NCT01814761
Status:
COMPLETED
Last Update Posted:
2015-10-26
First Post:
2013-03-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Bimatoprost 0.01% in the Clinical Setting
Sponsor:
Allergan
Organization:
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2015-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
APPEAL-Taiwan
Brief Summary:
This is a study of bimatoprost 0.01% (LUMIGAN® 0.01%) in subjects with primary open-angle glaucoma (POAG) or ocular hypertension (OH) who require further treatment for elevated intraocular pressure (IOP).
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: